大洋洲 · 股市与财经 · Stockhead
Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate
CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and ... Read More The post Health Check: CSL places…
在 Stockhead 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (stockhead.com.au)
